Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomea Fusion, Inc.

2.68
+0.15005.93%
Volume:535.57K
Turnover:1.43M
Market Cap:97.12M
PE:-0.67
High:2.81
Open:2.54
Low:2.54
Close:2.53
Loading ...

Biomea Fusion Announces Positive Topline Results From Ongoing Phase Ii Covalent-111 Study in Patients With Type 2 Diabetes

THOMSON REUTERS
·
17 Dec 2024

Biomea Fusion Inc - Icovamenib Meets Primary Endpoint With Significant Reduction in Hba1c

THOMSON REUTERS
·
17 Dec 2024

Biomea Fusion Inc - Icovamenib Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
17 Dec 2024

Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Dec 2024

Biomea Fusion’s Innovative Diabetes Therapy Boosts Buy Rating with Promising Preclinical Data on Icovamenib

TIPRANKS
·
16 Dec 2024

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22Nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)

THOMSON REUTERS
·
13 Dec 2024

Cautious Outlook on Biomea Fusion: Hold Rating Amid Clinical and Financial Uncertainties

TIPRANKS
·
10 Dec 2024

Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Dec 2024

Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours

MT Newswires Live
·
10 Dec 2024

Biomea Fusion announces preliminary COVALENT-103 study data

TIPRANKS
·
10 Dec 2024

BRIEF-Biomea Fusion Announces Preliminary Data From Ongoing Covalent-103 Study Of Investigational Covalent Flt3 Inhibitor Bmf-500 In Relapsed Or Refractory Acute Leukemia

Reuters
·
10 Dec 2024

Biomea Fusion Inc - Preliminary Data Supports Bmf-500 as Transformative Therapy for Flt3 Mutated R/R Acute Leukemia

THOMSON REUTERS
·
10 Dec 2024

Biomea Fusion Inc - Bmf-500 Shows Favorable Safety Profile With No Dose-Limiting Toxicities

THOMSON REUTERS
·
10 Dec 2024

Biomea Fusion, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 Dec 2024

Scotiabank Sticks to Their Buy Rating for Biomea Fusion (BMEA)

TIPRANKS
·
25 Nov 2024

Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Nov 2024